Patient-Focused Drug Development High On Industry’s List Of PDUFA VI Tweaks
Executive Summary
BIO and PhRMA want patient input gathered through a more structured and data-driven process than the current disease area meetings under PDUFA V, which are “anecdotal” in nature; National Organization for Rare Disorders seeks an interactive portal between patient community and FDA reviewers.
You may also be interested in...
US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'
FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
Drug reviews will include a benefit-risk summary assessment that states the rationale for regulatory action on a drug or biologic application and explains how differences of opinion among reviewers were resolved.
BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review
A November 2022 refuse-to-file letter cited clinical and statistical issues for the stem cell therapy, which failed its Phase III clinical efficacy endpoint. However, BrainStorm has consistently asserted that NurOwn demonstrated benefit in patients with less advanced disease at baseline, and it is encouraged by regulatory flexibility FDA recently has shown for the neurodegenerative disease.